D-Optimal mixture design optimization of an HPLC method for simultaneous determination of commonly used antihistaminic parent molecules and their active metabolites in human serum and urine.

This study describes a specific, precise, sensitive and accurate method for simultaneous determination of hydroxyzine, loratadine, terfenadine, rupatadine and their main active metabolites cetirizine, desloratadine and fexofenadine, in serum and urine using meclizine as an internal standard. Solid-phase extraction method for sample clean-up and preconcentration of analytes was carried out using Phenomenex Strata-X-C and Strata X polymeric cartridges. Chromatographic analysis was performed on a Phenomenex cyano (150 × 4.6 mm i.d., 5 µm) analytical column. A D-optimal mixture design methodology was used to evaluate the effect of changes in mobile phase compositions on dependent variables and optimization of the response of interest. The mixture design experiments were performed and results were analyzed. The region of ideal mobile phase composition consisting of acetonitrile-methanol-ammonium acetate buffer (40 mm; pH 3.8 adjusted with acetic acid): 18:36:46% v/v/v was identified by a graphical optimization technique using an overlay plot. While using this optimized condition all analytes were baseline resolved in <10 min. Solvent mixtures were delivered at 1.5 mL/min flow rate and analytes peaks were detected at 222 nm. The proposed bioanalytical method was validated according to US Food and Drug Administration guidelines. The proposed method was sensitive with detection limits of 0.06-0.15 µg/mL in serum and urine samples. Relative standard deviation for inter- and intra-day precision data was found to be <7%. The proposed method may find application in the determination of selected antihistaminic drugs in biological fluids.

Robust analysis of the hydrophobic basic analytes loratadine and desloratadine in pharmaceutical preparations and biological fluids by sweeping-cyclodextrin-modified micellar electrokinetic chromatography.

The analysis of hydrophobic basic analytes by micellar electrokinetic chromatography (MEKC) is usually challenging because of the tendency of these analytes to be adsorbed onto the inner capillary wall in addition to the difficulty to separate these compounds as they exhibit extremely high retention factors. A robust and reliable method for the simultaneous determination of loratadine (LOR) and its major metabolite desloratadine (DSL) is developed based on cyclodextrin-modified micellar electrokinetic chromatography (CD-MEKC) with acidic sample matrix and basic background electrolyte (BGE). The influence of the sample matrix on the reachable focusing efficiency is studied. It is shown that the application of a low pH sample solution mitigates problems associated with the low solubility of the hydrophobic basic analytes in aqueous solution while having advantages with regard to on-line focusing. Moreover, the use of a basic BGE reduces the adsorption of these analytes in the separation compartment. The separation of the studied analytes is achieved in less than 7min using a BGE consisting of 10mmolL(-1) disodium tetraborate buffer, pH 9.30 containing 40mmolL(-1) SDS and 20mmolL(-1) hydroxypropyl-ß-CD while the sample solution is composed of 10mmolL(-1) phosphoric acid, pH 2.15. A full validation study of the developed method based on the pharmacopeial guidelines is performed. The method is successfully applied to the analysis of the studied drugs in tablets without interference of tablet additives as well as the analysis of spiked human urine without any sample pretreatment. Furthermore, DSL can be detected as an impurity in LOR bulk powder at the stated pharmacopeial limit (0.1%, w/w). The selectivity of the developed method allows the analysis of LOR and DSL in combination with the co-formulated drug pseudoephedrine. It is shown that in CD-MEKC with basic BGE, solute-wall interactions are effectively suppressed allowing the development of efficient and precise methods for the determination of hydrophobic basic analytes, whereas the use of a low pH sample solution has a positive impact on the attainable sweeping efficiency without compromising peak shape and resolution.

Molecularly imprinted nano particles combined with miniaturized homogenous liquid-liquid extraction for the selective extraction of loratadine in plasma and urine samples followed by high performance liquid chromatography-photo diode array detection.

In this work a molecularly imprinted polymer was developed as a selective sorbent for extraction of loratadine (as a model) in complex matrices followed by miniaturized homogeneous liquid-liquid extraction (MHLLE) for the first time. The molecularly imprinted polymer (MIP) which is based on loratadine as the template was synthesized successfully by precipitation polymerization and was used as a selective sorbent. This technique was applied for preconcentration, sample preparation, and determination of loratadine using high performance liquid chromatography-photo diode array detection (HPLC-PDA). Optimization of various parameters affecting molecular imprinted solid phase extraction (MISPE), such as pH of adsorption, composition and volume of eluent, adsorption and desorption times were investigated. Besides, in the subsequent stage (MHLLE) the type and volume of extraction solvent, sodium hydroxide amount, surfactant concentration, and extraction time were investigated and optimized. Under the optimal condition, maximum enrichment capacity and Langmuir constant were 91mgg(-1) and 0.014Lmg(-1), respectively. Furthermore, enrichment factor and extraction recovery of MIP-MHLLE method were 30 and 90%, respectively. The LOD of the proposed method was 0.2µgL(-1) and a linear dynamic range of 1-1000µgL(-1) was obtained with correlation coefficient of greater than 0.998. The present method was applied for extraction and determination of loratadine in plasma and urine samples in µgL(-1) levels and satisfactory results were achieved (RSD <8% based on three replicate measurements).